Rapamycin generic is Sirolimus. The cost out of pocket depending on weekly 3-6mg dose is between $65-130 a month. Rapa is not a ”magic bullet” to cure AD. It is a medicine that inhibits Mtor1 and not Mtor2 when used weekly. By inhibiting Mtor the result is that autophagy takes place at a cellular level. The same autophagy that occurs when fasting. Rapa induces this autophagy greater than fasting, so in a way it’s an “easy” way to achieve with better results what hard work and discipline take with diet and will power. However, I still intermittent fast and consider it a staple of my health plan. The inhibiting of Mtor never allows plaques and tangles to form. Using a BP medicine to lower pressure for hypertension over decades keeps inflammation down. This keeps the vascular system from having a catastrophic event, resulting in a heart attack or stroke. Rapamycin if administered before the onset of AD, will lower Mtor and keep the cerebrovascular system healthy. The result is that you never get AD. So it’s not a cure. It’s a preventative medicine to never get it in the first place. There is so much information on Rapa from validated studies from mice to dogs that shows it lowers Mtor, prevents cancer, keeps AD from forming, etc. It has been used on over a million patients so far for organ transplants, so use in humans is established. The side effects are related to daily doses (organ transplant patients) whose Mtor1 and Mtor2 are both lowered. People interested in longevity have started to use it daily for life extension. It has been proven to increase life span 20-30% across all animals studied. If the average male lives to 78, than Rapa would extend their lives to 101. The patents have expired for Rapa so there is no incentive for pharma to investigate its properties further. For my purposes, by taking it for the next two decades I will halt the progress of cebrovascular damage in its tracks and never have to deal with AD. Giving me the odds of an E3/E3 or even lower with lifestyle modifications. Dr. Green currently has two E4/4 patients. One is in their mid 60s and the other is early 70s. A population sample of two is not groundshaking. However, statistically if both the patients in 10 years show zero cognitive deterioration, than the odds of that happening would be more than mere chance. That will be convincing enough for me.